Unaudited Condensed Consolidated Statement of Cash Flows - USD ($) $ in Thousands	3 Months Ended				6 Months Ended		12 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Cash flows from operating activities:
Net loss and comprehensive loss	$ (5,119)	$ (64,424)	$ (8,003)	$ 938	$ (69,543)	$ (7,065)
Adjustments to reconcile net loss to net cash provided by operations:
Share-based compensation					19,262	7,151
Depreciation and amortization					3,103	2,752
Transaction expenses related to the Merger					3,132	0
Amortization of right-of-use assets					1,961	1,317
Loss on impairment of long lived assets					446	0
Bad debt allowance					269	214
Change in fair value of warrant liabilities	(20,558)		5,404		5,402	6,312
Settlement of related party promissory notes (Note 3)					5,517	0
Other					0	125
Changes in operating assets and liabilities:
Accounts receivable					3,628	1,588
Prepaid expenses and other assets					(6,943)	178
Accounts payable					1,843	(113)
Accrued expenses and other liabilities					(1,182)	2,837
Accrued compensation and benefits					(12,676)	4,377
Operating lease liabilities					(2,581)	(1,735)
Net cash (used in) provided by operating activities					(48,362)	17,938
Cash flows from investing activities:
Purchases of property and equipment					(106)	0
Purchases of intangible assets					(97)	0	$ (2,202)
Capitalized internal-use software development costs					(3,232)	(406)
Net cash used in investing activities					(3,435)	(406)
Cash flows from financing activities:
Proceeds from the Merger					7,865	0
Proceeds from PIPE and A&R FPA investors					208,500	0
Payments for offering costs					(56,852)	(740)
Proceeds from exercise of Public Warrants					22,136	0
Proceeds from exercise of options, including proceeds from repayment of promissory notes					505	1,114
Repayment of notes payable					0	(19,437)
Payments to repurchase early exercised stock options					0	(3)
Net cash provided by financing activities					182,154	30,309
Net increase in cash and cash equivalents					130,357	47,841
Cash, cash equivalents and restricted cash, beginning of the period		76,404		42,178	76,404	42,178	42,178
Cash, cash equivalents and restricted cash, end of the period	206,761		90,019		206,761	90,019	76,404
Reconciliation of cash, cash equivalents and restricted cash to the amounts reported within the condensed consolidated balance sheets
Cash and cash equivalents	204,942		88,396		204,942	88,396	74,781
Restricted cash	1,819		1,623		1,819	1,623	1,623
Total cash, cash equivalents and restricted cash, end of the period	206,761		90,019		206,761	90,019	$ 76,404
Supplemental disclosures of cash flow information:
Cash paid for interest					0	2,118
Supplemental disclosure of non-cash investing and financing activities:
Capitalized internal-use software development costs accrued and not yet paid					386	91
Reclassification of deferred offering costs to equity					5,923	0
Conversion of preferred stock					246,049	0
Conversion of May 2020 and October 2020 preferred stock warrants of Legacy Forge to common stock warrants					2,949	0
Non-cash assets acquired in the Merger					193	0
Warrants issued in connection with FPA					3,080	0
Assumption of merger warrants liability					13,983	0
Recapitalization of Legacy Forge common stock					5	0
Exchange of Class AA common stock for Series B-1 convertible preferred stock					0	39,722
Vesting of early exercised stock options and restricted stock awards	$ 638	$ 409	$ 45	$ 11	1,048	56
Warrant liability reclassified to additional paid-in capital upon excercise of Public Warrants					698	0
Issuance of common stock upon settlement of promissory notes					4,207	0
Early exercise of stock options upon settlement of related party promissory notes					1,310	0
Series B-1
Cash flows from financing activities:
Proceeds from issuance of convertible preferred stock, net of issuance costs					0	47,735
Series B-2
Cash flows from financing activities:
Proceeds from issuance of convertible preferred stock, net of issuance costs					$ 0	$ 1,640